Celadon Pharmaceuticals Plc - Finance Update Received final £103k from its £1.0m draw down request Celadon has also received a £389k tax credit from a R&D claim londonstockexchange.com/news-article/C… #CEL #Medical #Cannabis #CeladonPharmaceuticals #Innovation

Revealed: Boom in private market for medical cannabis Eligible patients finding it impossible to obtain medical supply through NHS despite 2018 legalisation telegraph.co.uk/news/2025/02/1… #CEL #Medical #Cannabis #CeladonPharmaceuticals #Innovation #Collaboration #Growth

The mainstream media is well known for getting cannabis research wrong. Is sensationalism the reason NHS doctors are reluctant to accept the medical benefits of cannabis? leafie.co.uk/articles/media… #CEL #Medical #Cannabis #CeladonPharmaceuticals #Innovation

Cannabis-based medicines have shown rapid growth internationally, with a growing evidence base for its role in treating a variety of conditions (e.g. epilepsy, multiple sclerosis, autism). Celadon’s primary focus is chronic pain – a large, unaddressed market (8 million adults in

Celadon Pharmaceuticals Plc - New Committed Credit Facility Celadon Pharmaceuticals Plc announces that it has entered into a £1.95 million, three year secured committed credit facility with a Swiss-based individual lender. londonstockexchange.com/news-article/C… #CEL #Medical #Cannabis

"We are pleased to have secured funding through the Facility at such an important time in the Company's growth journey.  This Facility will support the growth in our operations to meet the growing interest in Celadon's product. "The additional flexibility that this brings to the

The three year secured committed credit facility with a Swiss-based individual lender is in addition to the existing unsecured £7.0m committed credit facility. As part of entering into the Facility the Company obtained a waiver from the Existing Facility provider to prevent any

While NHS progress remains stagnant, private cannabis clinics such as Releaf, are seeing growing numbers of patients report positive effects of cannabis-based treatments for a wide range of conditions. cannabishealthnews.co.uk/2025/02/27/clo… #CEL #Medical #Cannabis #CeladonPharmaceuticals

Celadon’s primary focus is chronic pain – a large, unaddressed market (8 million adults in the UK, 50 million in the US, 100 million in Europe), with many problems with existing opioid treatments. #CEL #Medical #Cannabis #CeladonPharmaceuticals #Biotech #Healthcare #ChronicPain

Celadon is one of the first UK companies to be awarded licences by UK regulators and MHRA to cultivate and manufacture high-THC medicinal cannabis. The company operates in a highly regulated environment and as such is committed to the following standards and licences: Controlled

Record numbers of Scots are paying for medical cannabis as NHS waiting lists leave them struggling to get conventional treatment. An unprecedented 3,440 Scots now have private prescriptions for the drug – mostly patients suffering from common conditions such as depression,

A survey has revealed that 84% of UK doctors would be willing to prescribe medical cannabis to manage chronic pain if it were part of the NHS toolkit. The research, commissioned by medical cannabis clinic Alternaleaf, comes as experts warn that the number of chronic pain

In 2024, the UK’s total medical cannabis flower imports more than doubled, rising from nearly 7 tonnes in 2023 to over 15 tonnes in 2024. For the year to date, the UK has imported just over 2 tonnes, nearly half of which was sourced from Spain. businessofcannabis.com/uk-has-importe… #CEL

Celadon Pharmaceuticals Plc - Funding Update londonstockexchange.com/news-article/C… #CEL #Medical #Cannabis

Celadon continues to engage closely with all creditors and stakeholders to ensure sufficient liquidity through April 2025, with the new facility expected to support operations into Q3 2025. #CEL #Medical #Cannabis #CeladonPharmaceuticals

Celadon Pharmaceuticals Plc - Board Changes and De-Listing Proposal londonstockexchange.com/news-article/C… #CEL #Medical #Cannabis

Celadon Pharmaceuticals Plc would like to address a number of enquiries received from shareholders regarding the RNS announcement this morning (24th March 2025), in which the Company proposed to seek shareholder approval to delist from AIM. 𝟭. 𝗬𝗼𝘂𝗿 𝗦𝗵𝗮𝗿𝗲𝘀

Celadon Pharmaceuticals Plc - Funding Update londonstockexchange.com/news-article/C… #CEL #Medical #Cannabis

UK adults remain confused about the legal status and availability of medical cannabis, despite it being legalised in 2018, a new survey has revealed.  cannabishealthnews.co.uk/2025/03/26/qua… #CEL #Medical #Cannabis #CeladonPharmaceuticals

Although nearly three-quarters of the Scottish public are misinformed about the legal status of medicinal cannabis, support for it in Scotland is higher than in most other parts of the United Kingdom. scotsman.com/read-this/6-re… #CEL #Medical #Cannabis #CeladonPharmaceuticals